Abstract | OBJECTIVE: DATA IDENTIFICATION: Articles were identified via an English-language literature search of MEDLINE (1966-91) and an extensive search of bibliographies from identified articles. STUDY SELECTION: Human clinical trials and case reports were selected for evaluation. DATA EXTRACTION: The literature was assessed for quality, methodology, and outcome information. DATA SYNTHESIS: At dosages of 4 mg/m2 administered every other week for 6-9 months, pentostatin has been shown to successfully induce a complete response in 58-90 percent of patients and to produce a partial response in up to 30 percent of patients with HCL. The median time to achieve a response is 4.7 months. Long-term remissions of at least 14 months' duration have occurred in some patients. Compared with interferon alfa alone, total response rates are not significantly different when pentostatin and interferon alfa are used in combination. When dosed appropriately, pentostatin is generally well tolerated. Common adverse effects include nausea, vomiting, myelosuppression, fever, and infection. CONCLUSIONS:
|
Authors | B J Kane, J G Kuhn, M K Roush |
Journal | The Annals of pharmacotherapy
(Ann Pharmacother)
1992 Jul-Aug
Vol. 26
Issue 7-8
Pg. 939-47
ISSN: 1060-0280 [Print] United States |
PMID | 1504408
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
|
Chemical References |
- Adenosine Deaminase Inhibitors
- Interferon-alpha
- Pentostatin
|
Topics |
- Adenosine Deaminase Inhibitors
- Age Factors
- Clinical Trials as Topic
- Drug Interactions
- Humans
- Interferon-alpha
(administration & dosage)
- Leukemia, Hairy Cell
(drug therapy)
- Pentostatin
(adverse effects, pharmacokinetics, pharmacology)
|